Ali, S.R., Ranjbarvaziri, S., Talkhabi, M., Zhao, P., Subat, A., Hojjat, A., Kamran, P., Müller, A.M.S., Volz, K.S., Tang, Z., Red-Horse, K., Ardehali, R., 2014.
Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation. Circ. Res. 115, 625–635.
doi:10.1161/CIRCRESAHA.115.303794
Asch, A.S., Tepler, J., Silbiger, S., Nachman, R.L., 1991. Cellular attachment to thrombospondin: Cooperative interactions between receptor systems. J. Biol.
Chem. 266, 1740–1745.
Banerjee, I., Fuseler, J.W., Price, R.L., Borg, T.K., Baudino, T.A., 2007.
Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. AJP Hear. Circ. Physiol. 293, 1883–1891.
doi:10.1152/ajpheart.00514.2007
Bergman, D., Halje, M., Nordin, M., Engström, W., 2013. Insulin-like growth factor 2 in development and disease: A mini-review. Gerontology. 59, 240-249.
doi:10.1159/000343995
Bowers, S.L.K., Banerjee, I., Baudino, T.A., 2010. The extracellular matrix: At the center of it all. J. Mol. Cell. Cardiol. 48, 474–482.
doi:10.1016/j.yjmcc.2009.08.024
Bowers, S.L.K., McFadden, W.A., Borg, T.K., Baudino, T.A., 2012. Desmoplakin is important for proper cardiac cell-cell interactions. Microsc. Microanal. 18, 107–114. doi:10.1017/S1431927611012359
Brown, R.D., Ambler, S.K., Mitchell, M.D., Long, C.S., 2005. THE CARDIAC FIBROBLAST: Therapeutic Target in Myocardial Remodeling and Failure.
Annu. Rev. Pharmacol. Toxicol. 45, 657–687.
doi:10.1146/annurev.pharmtox.45.120403.095802
Camelliti, P., Borg, T.K., Kohl, P., 2005. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res.65, 40-51.
doi:10.1016/j.cardiores.2004.08.020
Camelliti, P., Devlin, G.P., Matthews, K.G., Kohl, P., Green, C.R., 2004. Spatially and temporally distinct expression of fibroblast connexins after sheep
ventricular infarction. Cardiovasc. Res. 62, 415–425.
doi:10.1016/j.cardiores.2004.01.027
Catalucci, D., Latronico, M.V.G., Ellingsen, O., Condorelli, G., 2008. Physiological myocardial hypertrophy: how and why? Front. Biosci. 13, 312–324.
doi:10.2741/2681
Cerrato, F., Sparago, A., Verde, G., De Crescenzo, A., Citro, V., Cubellis, M.V., Rinaldi, M.M., Boccuto, L., Neri, G., Magnani, C., D’Angelo, P., Collini, P., Perotti, D., Sebastio, G., Maher, E.R., Riccio, A., 2008. Different mechanisms cause imprinting defects at the IGF2/H19 locus in Beckwith - Wiedemann syndrome and Wilms’ tumour. Hum. Mol. Genet. 17, 1427–1435.
doi:10.1093/hmg/ddn031
Charron, F., Paradis, P., Bronchain, O., Nemer, G., Nemer, M., 1999. Cooperative interaction between GATA-4 and GATA-6 regulates myocardial gene
expression. Mol. Cell. Biol. 19, 4355–65. doi:10.1128/MCB.19.6.4355 Chistiakov, D.A., Orekhov, A.N., Bobryshev, Y. V., 2016. The role of cardiac
fibroblasts in post-myocardial heart tissue repair. Exp. Mol. Pathol. 101, 231-240. doi:10.1016/j.yexmp.2016.09.002
Chu, L.Y., Ramakrishnan, D.P., Silverstein, R.L., 2013. Thrombospondin-1
modulates VEGF signaling via CD36 by recruiting SHP-1 to VEGFR2 complex in microvascular endothelial cells. Blood. 122, 1822–1832. doi:10.1182/blood-2013-01-482315
Cohn, J.N., Ferrari, R., Sharpe, N., 2000. Cardiac remodeling-concepts and clinical implications: A consensus paper from an International Forum on Cardiac Remodeling. J. Am. Coll. Cardiol. 35, 569–582. doi:10.1016/S0735-1097(99)00630-0
Corda, S., Samuel, J.-L., Rappaport, L., 2000. Extracellular matrix and growth factors during heart growth. Heart Fail. Rev. 5, 119–130.
doi:10.1023/A:1009806403194
Cowie, M.R., Poole-Wilson, P., 2013. Pathophysiology of heart failure. In:
Rosendorff C, ed. Essential cardiology. 3rd edn., New York: Springer.
Dostal, D., Glaser, S., Baudino, T.A., 2015. Cardiac fibroblast physiology and pathology. Compr. Physiol. 5, 887–909. doi:10.1002/cphy.c140053 Ernst, A., Köhrle, J., Bergmann, A., 2006. Proenkephalin A 119–159, a stable
proenkephalin A precursor fragment identified in human circulation. Peptides.
27, 1835–1840. doi:10.1016/j.peptides.2006.03.008
Fan, D., Takawale, A., Lee, J., Kassiri, Z., 2012. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair.
5,15. doi:10.1186/1755-1536-5-15
Frangogiannis, N.G., Frangogiannis, G., N., 2015. Pathophysiology of Myocardial Infarction, in: Comprehensive Physiology. John Wiley & Sons, Inc., Hoboken, NJ, USA.1841–1875. doi:10.1002/cphy.c150006
Froese, N., Kattih, B., Breitbart, A., Grund, A., Geffers, R., Molkentin, J.D., Kispert, A., Wollert, K.C., Drexler, H., Heineke, J., 2011. GATA6 promotes angiogenic function and survival in endothelial cells by suppression of autocrine
transforming growth factor beta/activin receptor-like kinase 5 signaling. J. Biol.
Chem. 286, 5680–5690. doi:10.1074/jbc.M110.176925
Furtado, M.B., Costa, M.W., Pranoto, E.A., Salimova, E., Pinto, A.R., Lam, N.T., Park, A., Snider, P., Chandran, A., Harvey, R.P., Boyd, R., Conway, S.J., Pearson, J., Kaye, D.M., Rosenthal, N.A., 2014. Cardiogenic genes
expressed in cardiac fibroblasts contribute to heart development and repair.
Circ. Res. 114, 1422–1434. doi:10.1161/CIRCRESAHA.114.302530
Furtado, M.B., Nim, H.T., Boyd, S.E., Rosenthal, N.A., 2016. View from the heart:
cardiac fibroblasts in development, scarring and regeneration, Development.
143, 387-397. doi:10.1242/dev.120576
Garrington, T.P., Johnson, G.L., 1999. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr. Opin. Cell Biol. 11, 211-218. doi:10.1016/S0955-0674(99)80028-3
Haberland, M., Montgomery, R.L., Olson, E.N., 2009. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10, 32–42. doi:10.1038/nrg2485
Heineke, J., Auger-Messier, M., Xu, J., Oka, T., Sargent, M.A., York, A., Klevitsky, R., Vaikunth, S., Duncan, S.A., Aronow, B.J., Robbins, J., Cromblehol, T.M., Molkentin, J.D., 2007. Cardiomyocyte GATA4 functions as a
stress-responsive regulator of angiogenesis in the murine heart. J. Clin. Invest. 117, 3198–3210. doi:10.1172/JCI32573
Heineke, J., Molkentin, J.D., 2006. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol. 7, 589–600.
doi:10.1038/nrm1983
Herzig, T.C., Jobe, S.M., Aoki, H., Molkentin, J.D., Cowley, A.W., Izumo, S., Markham, B.E., 1997. Angiotensin II type1a receptor gene expression in the heart: AP-1 and GATA-4 participate in the response to pressure overload.
Proc. Natl. Acad. Sci. 94, 7543–7548. doi:10.1073/pnas.94.14.7543
Humphries, M.J., Reynolds, A., 2009. Cell-to-cell contact and extracellular matrix.
Curr. Opin. Cell Biol. 21, 613–615. doi:10.1016/j.ceb.2009.09.001
Imai, N., Kashiki, M., Woolf, P.D., Liang, C.S., 1994. Comparison of cardiovascular effects of mu- and delta-opioid receptor antagonists in dogs with congestive heart failure. Am. J. Physiol. 267, H912-H917.
doi: 10.1152/ajpheart. 1994. 267.3.H912
Izumiya, Y., Shiojima, I., Sato, K., Sawyer, D.B., Colucci, W.S., Walsh, K., 2006.
Vascular Endothelial Growth Factor Blockade Promotes the Transition From Compensatory Cardiac Hypertrophy to Failure in Response to Pressure Overload. Hypertension. 47, 887–893.
doi:10.1161/01.HYP.0000215207.54689.31
Jiménez, B., Volpert, O. V., Crawford, S.E., Febbraio, M., Silverstein, R.L., Bouck, N., 2000. Signals leading to apoptosis-dependent inhibition of
neovascularization by thrombospondin-1. Nat. Med. 6, 41–48.
doi:10.1038/71517
Kakkar, R., Lee, R.T., 2010. Intramyocardial fibroblast myocyte communication.
Circ. Res. 106, 47-57. doi:10.1161/CIRCRESAHA.109.207456
Kawaguchi, M., Takahashi, M., Hata, T., Kashima, Y., Usui, F., Morimoto, H., Izawa, A., Takahashi, Y., Masumoto, J., Koyama, J., Hongo, M., Noda, T., Nakayama, J., Sagara, J., Taniguchi, S., Ikeda, U., 2011. Inflammasome activation of cardiac fibroblasts is essential for myocardial
ischemia/reperfusion injury. Circulation.123, 594–604.
doi:10.1161/CIRCULATIONAHA.110.982777
Kehat, I., Molkentin, J.D., 2010. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation.122, 2727–
2735. doi:10.1161/CIRCULATIONAHA.110.942268
Kohli, S., Ahuja, S., Rani, V., 2011. Transcription factors in heart: promising therapeutic targets in cardiac hypertrophy. Curr. Cardiol. Rev. 7, 262–271.
doi:10.2174/157340311799960618
Kong, P., Christia, P., Frangogiannis, N.G., 2014. The pathogenesis of cardiac fibrosis. Cell. Mol. Life Sci. 71, 549–574. doi:10.1007/s00018-013-1349-6 Lajiness, J.D., Conway, S.J., 2014. Origin, development, and differentiation of
cardiac fibroblasts. J. Mol. Cell. Cardiol. 70:2-8.
doi:10.1016/j.yjmcc.2013.11.003
Liang, Q., De Windt, L.J., Witt, S.A., Kimball, T.R., Markham, B.E., Molkentin, J.D., 2001. The Transcription Factors GATA4 and GATA6 Regulate Cardiomyocyte Hypertrophy in Vitro and in Vivo. J. Biol. Chem. 276, 30245–30253.
doi:10.1074/jbc.M102174200
Liu, H., Chen, B., Lilly, B., 2008. Fibroblasts potentiate blood vessel formation partially through secreted factor TIMP-1. Angiogenesis. 11, 223–234.
doi:10.1007/s10456-008-9102-8
Matsue, Y., Ter Maaten, J.M., Struck, J., Metra, M., O ’connor, C.M., Ponikowski, P., Teerlink, J.R., Cotter, G., Davison, B., Cleland, J.G., Givertz, M.M., Bloomfield, D.M., Dittrich, H.C., Van Veldhuisen, D.J., Van Der Meer, P., Damman, K., Voors, A.A., 2016. Clinical Correlates and Prognostic Value of
Proenkephalin in Acute and Chronic Heart Failure. J. Card. Fail. 23, 231–239.
doi:10.1016/j.cardfail.2016.09.007
Mohamed, T.M.A., Abou-Leisa, R., Stafford, N., Maqsood, A., Zi, M., Prehar, S., Baudoin-Stanley, F., Wang, X., Neyses, L., Cartwright, E.J., Oceandy, D., 2016. The plasma membrane calcium ATPase 4 signalling in cardiac fibroblasts mediates cardiomyocyte hypertrophy. Nat. Commun. 7, 11074.
doi:10.1038/ncomms11074
Molkentin, J.D., 2000. The zinc finger-containing transcription factors GATA-4, -5, and -6: Ubiquitously expressed regulators of tissue-specific gene expression.
J. Biol. Chem. 275,38949-38952. doi:10.1074/jbc.R000029200
Molkentin, J.D., Lu, J.R., Antos, C.L., Markham, B., Richardson, J., Robbins, J., Grant, S.R., Olson, E.N., 1998. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 93, 215–228. doi:10.1016/S0092-8674(00)81573-1
Moore-Morris, T., Guimarães-Camboa, N., Banerjee, I., Zambon, A.C., Kisseleva, T., Velayoudon, A., Stallcup, W.B., Gu, Y., Dalton, N.D., Cedenilla, M.,
Gomez-Amaro, R., Zhou, B., Brenner, D.A., Peterson, K.L., Chen, J., Evans, S.M., 2014. Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. J. Clin. Invest. 124, 2921–2934. doi:10.1172/JCI74783 Morimoto, T., Hasegawa, K., Kaburagi, S., Kakita, T., Wada, H., Yanazume, T.,
Sasayama, S., 2000. Phosphorylation of GATA-4 is involved in α1-Adrenergic Agonist- responsive transcription of the endothelin-1 gene in cardiac
myocytes. J. Biol. Chem. 275, 13721–13726. doi:10.1074/jbc.275.18.13721 Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M.,
Das, S.R., De Ferranti, S., Després, J.P., Fullerton, H.J., Howard, V.J., Huffman, M.D., Isasi, C.R., Jiménez, M.C., Judd, S.E., Kissela, B.M.,
Lichtman, J.H., Lisabeth, L.D., Liu, S., MacKey, R.H., Magid, D.J., McGuire, D.K., Mohler, E.R., Moy, C.S., Muntner, P., Mussolino, M.E., Nasir, K., Neumar, R.W., Nichol, G., Palaniappan, L., Pandey, D.K., Reeves, M.J., Rodriguez, C.J., Rosamond, W., Sorlie, P.D., Stein, J., Towfighi, A., Turan, T.N., Virani, S.S., Woo, D., Yeh, R.W., Turner, M.B., 2016. Executive
summary: Heart disease and stroke statistics-2016 update: A Report from the American Heart Association. Circulation. 133, e38-360.
doi:10.1161/CIR.0000000000000366
Murakami, M., Simons, M., 2008. Fibroblast growth factor regulation of neovascularization. Curr. Opin. Hematol. 15, 215–220.
doi:10.1097/MOH.0b013e3282f97d98
Nag, A.C., 1980. Study of non-muscle cells of the adult mammalian heart: a fine structural analysis and distribution. Cytobios 28, 41–61.
Ng, L.L., Sandhu, J.K., Narayan, H., Quinn, P.A., Squire, I.B., Davies, J.E., Bergmann, A., Maisel, A., Jones, D.J.L., 2014. Proenkephalin and prognosis after acute myocardial infarction. J. Am. Coll. Cardiol. 63, 280–289.
doi:10.1016/j.jacc.2013.09.037
Oka, T., Maillet, M., Watt, A.J., Schwartz, R.J., Aronow, B.J., Duncan, S.A., Molkentin, J.D., 2006. Cardiac-specific deletion of gata4 reveals its
requirement for hypertrophy, compensation, and myocyte viability. Circ. Res.
98, 837–845. doi:10.1161/01.RES.0000215985.18538.c4
Olsen, M.W.B., Ley, C.D., Junker, N., Hansen, A.J., Lund, E.L., Kristjansen, P.E.G., 2006. Angiopoietin-4 inhibits angiogenesis and reduces interstitial fluid pressure. Neoplasia. 8, 364–372. doi:10.1593/neo.06127
Patient, R.K., McGhee, J.D., 2002. The GATA family (vertebrates and
invertebrates). Curr. Opin. Genet. Dev. 12, 416–422. doi:10.1016/S0959-437X(02)00319-2
Peterkin, T., Gibson, A., Loose, M., Patient, R., 2005. The roles of GATA-4, -5 and -6 in vertebrate heart development. Semin. Cell Dev. Biol. 16, 83-94.
doi:10.1016/j.semcdb.2004.10.003
Pikkarainen, S., Tokola, H., Kerkelä, R., Ruskoaho, H., 2004. GATA transcription factors in the developing and adult heart. Cardiovasc. Res. 63, 196-207.
doi:10.1016/j.cardiores.2004.03.025
Pinto, A.R., Ilinykh, A., Ivey, M.J., Kuwabara, J.T., D’antoni, M.L., Debuque, R., Chandran, A., Wang, L., Arora, K., Rosenthal, N.A., Tallquist, M.D., 2016.
Revisiting cardiac cellular composition. Circ. Res. 118, 400–409.
doi:10.1161/CIRCRESAHA.115.307778
Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G.F., Coats, A.J.S., Falk, V., González-Juanatey, J.R., Harjola, V.-P., Jankowska, E.A., Jessup, M., Linde, C., Nihoyannopoulos, P., Parissis, J.T., Pieske, B., Riley, J.P., Rosano, G.M.C., Ruilope, L.M., Ruschitzka, F., Rutten, F.H., van der Meer, P., 2016. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. J. Heart Fail. 18, 891–975. doi:10.1002/ejhf.592 Porter, K.E., Turner, N.A., 2009. Cardiac fibroblasts: At the heart of myocardial
remodeling. Pharmacol. Ther. 123, 255-278.
doi:10.1016/j.pharmthera.2009.05.002
Powell, D.W., Mifflin, R.C., Valentich, J.D., Crowe, S.E., Saada, J.I., West, A.B., 1999. Myofibroblasts. I. Paracrine cells important in health and disease. Am.
J. Physiol. Physiol. 277, C1–C19. doi:10.1086/316294
Ren, B., Best, B., Ramakrishnan, D.P., Walcott, B.P., Storz, P., Silverstein, R.L., 2016. LPA/PKD-1-FoxO1 signaling axis mediates endothelial cell CD36 transcriptional repression and proangiogenic and proarteriogenic
reprogramming. Arterioscler. Thromb. Vasc. Biol. 36, 1197–1208.
doi:10.1161/ATVBAHA.116.307421
Ren, B., Yee, K.O., Lawler, J., Khosravi-Far, R., 2006. Regulation of tumor angiogenesis by thrombospondin-1. Biochim. Biophys. Acta - Rev. Cancer.
1765, 178–188. doi:10.1016/j.bbcan.2005.11.002
Rodriguez, S., 2004. Haplotypic analyses of the IGF2-INS-TH gene cluster in relation to cardiovascular risk traits. Hum. Mol. Genet. 13, 715–725.
doi:10.1093/hmg/ddh070
Samani, A.A., Yakar, S., LeRoith, D., Brodt, P., 2007. The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights. Endocr.
Rev. 28, 20–47. doi:10.1210/er.2006-0001
Schirone, L., Forte, M., Palmerio, S., Yee, D., Nocella, C., Angelini, F., Pagano, F., Schiavon, S., Bordin, A., Carrizzo, A., Vecchione, C., Valenti, V., Chimenti, I., Falco, E. De, Sciarretta, S., Frati, G., 2017. A Review of the Molecular
Mechanisms Underlying the Development and Progression of Cardiac Remodeling. Oxid. Med. Cell. Longev. 2017. 2017,3920195
doi:10.1155/2017/3920195
Segura, A.M., Frazier, O.H., Buja, L.M., 2014. Fibrosis and heart failure. Heart Fail. Rev. 19, 173–185. doi:10.1007/s10741-012-9365-4
Shiojima, I., Sato, K., Izumiya, Y., Schiekofer, S., Ito, M., Liao, R., Colucci, W.S., Walsh, K., 2005. Disruption of coordinated cardiac hypertrophy and
angiogenesis contributes to the transition to heart failure. J. Clin. Invest. 115, 2108–2118. doi:10.1172/JCI24682
Souders, C.A., Bowers, S.L.K., Baudino, T.A., 2009. Cardiac Fibroblast: The Renaissance Cell. Circ. Res. 105, 1164–1176.
doi:10.1161/CIRCRESAHA.109.209809
Sun, Y., Weber, K.T., 2000. Infarct scar: a dynamic tissue. Cardiovasc. Res. 46, 250–256. doi:10.1016/S0008-6363(00)00032-8
Takeda, N., Manabe, I., Uchino, Y., Eguchi, K., Matsumoto, S., Nishimura, S., Shindo, T., Sano, M., Otsu, K., Snider, P., Conway, S.J., Nagai, R., 2010.
Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J. Clin. Invest. 120, 254-65 doi:10.1172/JCI40295
Tallquist, M.D., Molkentin, J.D., 2017. Redefining the identity of cardiac fibroblasts.
Nat. Rev. Cardiol. 14, 484–491. doi:10.1038/nrcardio.2017.57
Travers, J.G., Kamal, F.A., Robbins, J., Yutzey, K.E., Blaxall, B.C., 2016. Cardiac fibrosis: The fibroblast awakens. Circ. Res. 118, 1021–1040. doi: 10.1161 /CIRCRESAHA.115.306565
Van Berlo, J.H., Aronow, B.J., Molkentin, J.D., 2013. Parsing the roles of the transcription factors GATA-4 and GATA-6 in the adult cardiac hypertrophic response. PLoS One. 8, e84591. doi:10.1371/journal.pone.0084591
Van Berlo, J.H., Elrod, J.W., Van Den Hoogenhof, M.M.G., York, A.J., Aronow, B.J., Duncan, S.A., Molkentin, J.D., 2010. The transcription factor GATA-6 regulates pathological cardiac hypertrophy. Circ. Res. 107, 1032–1040.
doi:10.1161/CIRCRESAHA.110.220764
van den Brink, O.W. V, Delbridge, L.M., Rosenfeldt, F.L., Penny, D., Esmore, D.S., Quick, D., Kaye, D.M., Pepe, S., 2003. Endogenous cardiac opioids:
Enkephalins in adaptation and protection of the heart. Hear. Lung Circ. 12, 178-187. doi:10.1046/j.1444-2892.2003.00240.x
Waldo, K., Miyagawa-Tomita, S., Kumiski, D., Kirby, M.L., 1998. Cardiac Neural Crest Cells Provide New Insight into Septation of the Cardiac Outflow Tract:
Aortic Sac to Ventricular Septal Closure. Dev. Biol. 196, 129–144.
doi:10.1006/dbio.1998.8860
Wang, K.C., Botting, K.J., Padhee, M., Zhang, S., Mcmillen, I.C., Suter, C.M., Brooks, D.A., Morrison, J.L., 2012. Early origins of heart disease: Low birth weight and the role of the insulin-like growth factor system in cardiac
hypertrophy. Clin. Exp. Pharmacol. Physiol. 39, 958–964. doi:10.1111/j.1440-1681.2012.05743.x
Wu, Q.-Q., Xiao, Y., Yuan, Y., Ma, Z.-G., Liao, H.-H., Liu, C., Zhu, J.-X., Yang, Z., Deng, W., Tang, Q.-Z., 2017. Mechanisms contributing to cardiac remodelling.
Clin. Sci. (Lond). 131, 2319–2345. doi:10.1042/CS20171167
Xin, M., Davis, C.A., Molkentin, J.D., Lien, C.-L., Duncan, S.A., Richardson, J.A., Olson, E.N., 2006. A threshold of GATA4 and GATA6 expression is required for cardiovascular development. Proc. Natl. Acad. Sci. U. S. A. 103, 11189– 11194. doi:10.1073/pnas.0604604103
Yao, H., Han, X., Han, X., 2014. The Cardioprotection of the Insulin-Mediated PI3K/Akt/mTOR Signaling Pathway. Am. J. Cardiovasc. Drugs. 14, 433-442.
doi:10.1007/s40256-014-0089-9
Zaina, S., Pettersson, L., Thomsen, A.B., Chai, C.M., Qi, Z., Thyberg, J., Nilsson, J., 2003. Shortened life span, bradycardia, and hypotension in mice with targeted expression of an Igf2 transgene in smooth muscle cells.
Endocrinology. 144, 2695–2703. doi:10.1210/en.2002-220944
Zhang, C.L., McKinsey, T.A., Chang, S., Antos, C.L., Hill, J.A., Olson, E.N., 2002.
Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 110, 479–488. doi:10.1016/S0092-8674(02)00861-9
Zhao, L., Eghbali-Webb, M., 2001. Release of pro- and anti-angiogenic factors by human cardiac fibroblasts: Effects on DNA synthesis and protection under hypoxia in human endothelial cells. Biochim Biophys Acta - Mol. Cell Res.
1538, 273–282. doi:10.1016/S0167-4889(01)00078-7
Zhao, R., Watt, A.J., Battle, M.A., Li, J., Bondow, B.J., Duncan, S.A., 2008. Loss of both GATA4 and GATA6 blocks cardiac myocyte differentiation and results in acardia in mice. Dev. Biol. 317, 614–619. doi:10.1016/j.ydbio.2008.03.013 Zhou, H., Dickson, M.E., Kim, M.S., Bassel-Duby, R., Olson, E.N., 2015.
Akt1/protein kinase B enhances transcriptional reprogramming of fibroblasts to functional cardiomyocytes. Proc. Natl. Acad. Sci. 112, 11864–11869.
doi:10.1073/pnas.1516237112
Ziaeian, B., Fonarow, G.C., 2016. Epidemiology and aetiology of heart failure. Nat.
Rev. Cardiol. 13, 368–378. doi:10.1038/nrcardio.2016.25
9. Erklärung § 2 Abs. 2 Nr. 6 und 7 PromO
Ich erkläre, dass ich die der Medizinischen Hochschule Hannover zur Promotion eingereichte Dissertation mit dem Titel: Specific deletion of the transcription factors GATA4 and GATA6 in fibroblasts triggers cardiac dysfunction during pressure overload
aus der Klinik für Kardiologie und Angiologie der Medizinischen Hochschule Hannover
unter Betreuung von Prof. Dr. med. Jörg Heineke mit der Unterstützung durch Dr. Natali Froese
ohne sonstige Hilfe durchgeführt und bei der Abfassung der Dissertation keine anderen als die dort aufgeführten Hilfsmittel benutzt habe.
Die Gelegenheit zum vorliegenden Promotionsverfahren ist mir nicht kommerziell vermittelt worden. Insbesondere habe ich keine Organisation eingeschaltet, die gegen Entgelt Betreuerinnen und Betreuer für die Anfertigung von Dissertationen sucht oder die mir obliegenden Pflichten hinsichtlich der Prüfungsleistungen für mich ganz oder teilweise erledigt.
Ich habe diese Dissertation bisher an keiner in- oder ausländischen Hochschule zur Promotion eingereicht. Weiterhin versichere ich, dass ich den beantragten Titel bisher noch nicht erworben habe.
Ergebnisse der Dissertation wurden in keinem Publikationsorgan veröffentlicht.
Hannover, den _______________________
_______________________
(Unterschrift)
10. Acknowledgement
First, I would like to thank Prof. Jörg Heineke for giving me the opportunity to proceed in the Department of Cardiology and Angiology, Hannover Medical School for two and a half years. I really have gained a lot during my time here. He is a good teacher who give me great patience and valuable guidance in every stage of my study here. Without his constant encouragement and guidance, this thesis could not have reached its present form.
I shall extend my thanks to Dr. Natali Froese. She gave me a lot of supports in past two years. I appreciate her careful guidance and encouragement. She provided scientific guidance, participated in the discussions and organized the mouse line and my work. During preparation of the thesis, she has spent much time reading through each draft and provided me with inspiring advice.
My special thanks to the entire laboratory team: Frau Malgorzata Szaroszyk for her great efforts of operating mice, Frau Dr. Mona Malekmohammadi and Herr Dr.
Badder Kattih for the echocardiography. I’d like to thank Frau Dr. Andrea Grund, and Frau Dr. Gesine Scharf for the many good advice and help in all areas. I would like to thank everyone in our group who contributed directly or indirectly to the development of this project.
I would also like to give my acknowledgements to the dear technicians Frau Ulrike Schramek, Frau Anna Gigina, Frau Tamara Tuchel and Frau Nicole Erns for their technique supporting.
I am grateful to Prof. Mayr Manuel for analysis of ECM proteomics. Thanks to Dr.
Robert Geffers who helped us performed RNA-deep sequencing. I am also thankful to Dr. Daniela Fraccarollo for CFs isolation and sorting.
At the same time, I would grateful thank my motherland for providing me with the government scholarship to support my study and research in Germany.
Besides, Thanks all of my friends for accompanying with me during the past years.
We shared happiness and sadness. Thanks for their great friendship.
Above all, I would like to give my deepest gratitude and love to my family. In memory of my gone father-in-law Li Wu, and without supports of my father Qinglin Wang, mother Chuanhua Wei, mother-in-law Meiping Xu, husband Zhiqun Wu, my son Yifan Wu and my little daughter Yinuo Wu, nothing is possible.